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ABSTRACT
Introduction: The salivary gland (SG) in primary Sjögren’s syndrome (pSS) is characterized by its lack of
function (hyposalivation) and lymphocytic invasion. Small-molecule inhibitors (SMIs) are a new class of
drugs, whose diminutive size permits diffusion into cells. SMIs targeting components of the immune
system are eagerly being trialed for their potential therapeutic utility in pSS. Neglected until now,
however, is a discussion of the potential effects of SMIs on the SG epithelium.
Areas covered: We begin by reminding the reader of the SG epithelial compartment, its complicity in
inflammatory milieu formation in pSS, and categories of SMIs which merit attention. We discuss each SMI
category, including pre-clinical data concerning pSS and likely consequences of their application on the SG
epithelium.
Expert opinion: Recovery of saliva production in pSS requires restoring the function of the SG
epithelium, not solely on inflammation resolution. Many SMIs, for example, those blocking JAK-STAT
signaling, interfere with critical epithelial cell pathways, most notably EGF signaling. If the effect of SMIs
on SG epithelium is ignored, recovery of SG function will be challenging. We predict that NFκB signaling
blockade will impart the least SG epithelium damage whilst reducing inflammation and facilitating
recovery from hyposalivation in pSS.
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1. Introduction: small-molecule inhibitor use in
Sjögren’s syndrome
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune dis-
ease, frequently typified, amongstmanyother symptomsby loss of
function of the exocrine glands, autoantibody production and
chronic fatigue [1]. The immune landscape of pSS patients is
complex and has been described as conforming to a ‘type
I interferon signature’, in addition to active BAFF (also induced by
interferon), IL-6, IL-7, and IL-21 pathways [2,3]. The interferon
signature refers to the enhanced level of expression of interferon
genes themselves (α, β, ɣ), and their downstream targets, such as
IFIT1, IFIT3, IFI44L, IFI35, IFI44,MX1,OAS1, andSIGLEC [4]. Induction
of the interferon signature genes is physiologically indicative of
a viral infection, lending weight to the theory that pSS may origin-
ally, or at least partially, be caused by a latent/misprocessed viral
infection [5]. The BAFF/IL-6 and IL-21 pathways are likely to be
complicit in B-cell hyperactivity, as frequently observed in pSS [6].
In pSS, for as yet unclear reasons, salivary glands (SGs)
become infiltrated with lymphocytes. In fully developed pSS,
the infiltrate is predominantly composed of T- and B-cells and
coincides with dysfunction of the SG (hyposalivation). Although
lymphocytic infiltration was originally presumed to be causative
of SG dysfunction, this has recently been disputed, largely due to
the poor correlation between the amount of infiltration and
saliva production [7–9]. Some studies suggest indeed that
defects in calcium signaling, and specifically the Orai1, STIM1
and TRPC1 molecules involved in store-operated calcium entry
(SOCE), may underlie reduced saliva production prior to exten-
sive lymphocytic infiltration [10,11]. This ongoing dispute fosters
the continuing search for new agents to ameliorate hyposaliva-
tion in pSS patients, as research efforts continue to pinpoint why
saliva production diminishes. Small-molecule inhibitors (SMIs)
represent a relatively new class of chemicals, with weights of
under 900 Daltons. Their diminutive size permits diffusion across
cell membranes, facilitating transport to their intracellular sites of
action. Several publications have extensively reviewed the use of
SMIs in rheumatic diseases, including pSS [12–15]. These reviews
focus mostly on the effect of various SMIs on the immune cells
commonly associated with pSS. Here we take an alternative
approach. We aim to discuss possible uses and effects of SMIs
on the SG epithelium in pSS, and their eventual application to
facilitate regeneration of the damaged SG in pSS. We conclude
by suggesting that recovery of the function of the SG in pSS will
not be achieved without considering the effects of chosen drugs
on the SG epithelium.
2. The salivary gland epithelium in Sjögren’s
syndrome
In order to provide a full dissection of the potential effect of
SMIs on the SG epithelium, we will begin by outlining the
respective members in this cell compartment, the evidence of
their involvement in the immune response in pSS, and which
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SMIs in our opinion must be examined in terms of their effects
on the epithelium.
2.1. Types of salivary gland epithelial cells
The SG epithelium is comprised of several cell types (Figure 1).
Beginning at the foundations of saliva formation, acinar cells
produce and secrete either watery or mucous-rich saliva, from
serous and mucous acinar cells, respectively. In both cell types,
M3 muscarinic and α1 adrenergic neurotransmitter signaling
initiates the IP3R signaling pathway, releasing calcium via the
inositol triphosphate receptor (IP3R) from the endoplasmic
reticulum into the cytoplasm. This increased intracellular cal-
cium concentration triggers the action of the store-operated
calcium entry (SOCE) system. The concerted action of the
Orai1, TRPC1, and STIM1/2 trio of SOCE members in the
plasma membrane drives the movement of more calcium
into the cell [16]. The activation of water, potassium, and
chloride channels in response to this calcium deluge results
in water, and hence saliva, secretion out of the apical pole of
the acinar cell, via the aquaporin-5 channels [16]. Secretion is
facilitated by myoepithelial cells, which envelope the acinar
cell clusters and contract in response to cholinergic stimula-
tion to expel saliva. Secreted saliva is channeled through small
intercalated ducts into striated ducts, comprised of basal and
luminal cell types, and finally through the larger excretory
ducts into the mouth. Complementing these cell types and
critical for the sustained SG function are its resident stem/
progenitor cell populations. Stem/progenitor cells, from here
on termed SG progenitor cells (SGPCs) proliferate and differ-
entiate into fresh acinar cells, to replenish acinar cells reaching
the end of their lifespan. Human SGPCs are proposed to reside
in the intercalated and striated ductal compartments, with
some SGPC populations also being present in acini [17,18].
Although all of the above named cell types are epithelial in
nature, the term epithelium in pSS studies is usually used to
refer to the striated ducts. For the purpose of this review and
in keeping with the field, we will therefore also use the term
‘epithelial cells’ to refer to the striated ducts. Confusingly,
‘salivary gland epithelial cell (SGEC) cultures’, often used to
model the SG epithelium, may also contain intercalated duct
cell, acinar cells, and fibroblasts in addition to striated duct
cells. SGEC cultures are generated by mincing SG tissue,
Article Highlights
● Recovery of saliva production in patients with pSS requires rescue of
the saliva-producing SG epithelium, not solely resolution of
inflammation.
● Small molecular inhibitors (SMIs) targeting TLR, NFκB, and JAK-STAT
signaling, in addition to the autophagy machinery and Rho kinases
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tion of some SMIs for treatment of pSS patients may be detri-
mental to SG function.
● From the SMIs currently available and studies performed, blockade of
NFκB signaling using SMIs may represent the option with the least
collateral damage to the SG epithelium.
● There is a general lack of basic studies concerning the effect of SMIs
on the SG, which will hamper our ability to choose the most appro-
priate treatment modality.
● In order to model SMI induced damage on the whole SG epithelium,
not only the ductal cells, organoid cultures will likely become
a crucial tool.
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Figure 1. Epithelial cell types in the adult human parotid salivary gland. (a) Schematic representation of the five different types of epithelial cells in the adult human
salivary gland. The parotid gland contains serous acinar cells as secretory component, whereas the submandibular gland contains a mixture of serous and mucous
acinar cells. (b–e) Histological images showing a global view of a section of parotid gland tissue (b), and high-resolution images of striated ducts (c), an intercalated
duct (d), and the acinar cell/myoepithelial cell secretory unit (e). Hematoxylin-eosin staining.
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typically human minor (lip) biopsies, and depositing them into
tissue culture plates. A proportion of cells will adhere to the
plastic and proliferate to cover the surface of the dish, and are
used to study the SG epithelium [19]. SGECs according to
Dimitrou et al. are keratin 8, 18, and 19 positive, all of which
are broad SG epithelial markers, including acinar cells, and not
specific for the striated ducts [13]. Caution is recommended
when extrapolating properties of SGECs to striated duct
epithelial cells, and vice versa. Conversely, the recent increase
in comprehension of the nature of adult stem/progenitor cells
throughout the human body, and what they require to grow,
has facilitated their isolation from the SG, and indeed from
patients with pSS, in the form of organoids cultures (Figure 2)
[20]. Organoids, defined as ‘3D structure(s) grown from stem
cells and consisting of organ-specific cell types that self-
organizes through cell sorting and spatially restricted lineage
commitment’ represent miniature versions of their respective
organs of isolation, and contain not only progenitor cells but
also terminally differentiated functional cells such as acinar
cells [21]. As such organoids may be considered a superior
model for probing the mechanisms underlying hyposalivation
in pSS, and will presumably be employed more frequently in
the future to understand the SG in pSS.
2.2. Salivary gland epithelium as immune conductor
The SG epithelium as a whole was initially considered targeting
the process of SG damage in pSS, and at the receiving end of
immune signals. SGECs from pSS patients, for example, appear to
be more sensitive to apoptosis, undergoing more apoptosis when
stimulated with TNFα and IFNα. They are also likely to be an
important source of autoantigens, to undergo more detachment-
induced apoptosis (anoikis) by toll-like-receptor 3 ligation than
healthy controls, and to be susceptible to apoptosis induced by
pSS-associated B-cells [22–24]. Indeed, TLR3 stimulated SGECs also
demonstrated an enhanced mRNA level expression of the Ro60,
Ro52 and SSB autoantigens on their surfaces as a consequence of
apoptosis facilitating initiation of an immune response by immune
cells [25–27]. In addition to the increased apoptosis of epithelial
cells, the SG epithelium has also been demonstrated to contain
autophagy machinery that is less active [25,26,28,29]. Using SG
organoid cultures, we have recently demonstrated that the proin-
flammatory cytokines IFNα, TNFα, and IL-6 induce proliferation of
SG ductal cells, appearing to promote their premature transition
into replicative senescence [20]. We propose that this, in combina-
tion with SGPC apoptosis, may underpin persistent hyposalivation
state observed in pSS, as the cell pool normally responsible for
production of fresh acinar cells is exhausted [20].
Recently, various studies, focusing mostly on immunohisto-
chemical stainings has suggested that the epithelium actively
participates in the development of the immune milieu in pSS.
SGECs are capable of antigen presentation to the immune
system, by means of expression of MHC Class II, CD80, and
CD86 stimulatory/co-stimulatory molecules, all signals neces-
sary for T-cell activation [30,31]. SGECs also bind a variety of
pathogen-associated molecular patterns (PAMPs), as inferred
by expression of toll-like receptors (TLRs) 1, 2, 3, 4, and 7, and
express receptors for CXCL10, CXCL12, CXCL13, IFNα, IFNβ,
TNFα, in addition to the B-cell activator CD40 and it is receptor
CD40L [20,31–39]. They also produce a wide array of cyto-
kines/chemokines including IL-18, IL-21, IL-1, IL-6, TNFα,
BAFF, CXCL-10, CXCL-12, CXCL-13, and CCL-21 under various
stimulation conditions [19,32–44]. Taken altogether, it is there-
fore fair to assume that SMIs targeted at blockading general
immune system signaling pathways such as the NFκB, TLR and
JAK-STAT pathways may also exert an effect on the epithe-
lium, its progenitor cell population, and effect the subsequent
regenerative abilities of the SG. In support of the feasibility of
rescuing the SG epithelium in pSS, patients treated with
a biological DMARD rituximab demonstrated reversion of lym-
phoepithelial lesions, whereby striated ducts become invaded
by B-cells and proliferate, to normal ductal architecture [45].
2.3. Relevant SMIs for the epithelium in pSS
According to the clinicaltrials.gov website at the time of writing
and when searched under the disease type ‘Sjögren’s syndrome’
(last accessed February 2019), 17 of the 166 clinical pSS trials
registered are investigating the use of small-molecule inhibitors
for treatment of pSS [46]. The cellular pathways inhibited by these
agents include those blocking elements of the innate immune
response (TLR, NFκB, JAK-STAT and cathepsin S signaling), the
adaptive immune response (BTK and calcineurin signaling) and
the autophagy pathway (PI3K signaling, mTOR signaling).
Considering the presence of TLRs and cytokine receptors on SG
epithelial cells, and the implied activity of the NFκB pathway
downstream of TLR signaling, examination of the mechanism of
action of these SMIs is crucial. Inhibition of B-cells via Btk signaling
blockade or calcineurin signaling, or antigen presentation by
cathepsin S blockade conversely, will not be considered here.
Undoubtedly attenuation of B-cell proliferation, T-cell activation
and antigen presentation in the SG epithelium will have a knock-
on effect on the epithelium, which remains to be investigated. In
the interest of completeness, we will consider the effect so of
manipulation of the autophagy, apoptosis and Rho kinase path-
ways, three general cellular pathways for which no clinical trials
are as yet running for pSS, but for which attention may very likely
Figure 2. Representative phase contrast microscopy of salivary gland organoid
cultures from the human parotid gland.
EXPERT OPINION ON INVESTIGATIONAL DRUGS 3
turn to in the coming years. Available drugs targeting the path-
ways discussed are listed in Table 1.
3. Inhibitors of major immune signaling pathways
The fastest and first response of the body to attack by
a (perceived) foreign body is the triggering of the innate
immune system. Many immune responses being with TLR
signaling, whereby pathogen-specific molecular signals bind,
and activate the NFκB pathway, amongst other pathways.
Activated NFκB signaling then proceeds to initiate transcrip-
tion of proinflammatory genes such as cytokines. Secreted
cytokines are capable of activating neighboring cells and
transmitting signals through the JAK-STAT pathway. SMIs tar-
geting these crucial inflammatory signaling pathways are
commercially available and in clinical trials for use in pSS in
all of these signaling pathways. Each pathway will be consid-
ered with respect to its blockade in pSS and the potential
effect on the SG epithelium.
3.1. Inhibitors of toll-like receptor signaling
Pattern recognition receptors (PRRs) recognize pathogen-
associated molecular patterns (PAMPs), such a viral RNA, and
include the TLRs [49]. In humans, so far up to 10 different TLRs
have been identified. Endosomally located TLRs 3, 7, and 9
recognize viral RNA/DNA or CpG nucleotides, and their activa-
tion has traditionally been most commonly associated with
pSS. The activation of TLRs stimulates innate immune cells
such as macrophages and dendritic cells to produce inflam-
matory cytokines, induce dendritic cell functional maturation
and antigen presentation to naive T-cells [50]. Two cascades
are involved in TLR signal transduction process, involving
either Myd88 signaling (used by all TLRs except TLR3) and
TRIF signaling (used by all TLRs). These pathways are reviewed
in Takeda et al. [49] and culminate broadly speaking in NFκB
pathway activation. In pSS PBMCs, TLR7 and TLR9 mRNA levels
are upregulated, compared with healthy controls, and altered
TLR expression phenotype was found in pSS PBMCs [51]. At
present, no TLRs inhibitors are being evaluated in clinical trials
for pSS. A group of antimalarial drugs, however, namely
hydroxychloroquine sulfate (HCQ), chloroquine (CQ), and
quinacrine, have been applied to treat arthritis and SLE
patients [52]. These SMIs work by preventing endosome acid-
ification and TLR 7, 8 and 9 activation. CpG–52,364 is
a quinacrine derivative. A phase I trial of the use of CpG–
52,364 for SLE treatment has been completed, and results
are likely to be published in the near future. Another SMI of
TLRs, ST2825, which exerts its effects by inhibiting MyD88, has
been found to suppress TLR9 induced B-cell proliferation,
differentiation, and autoantibody production, showing poten-
tial therapeutic promise for pSS [53]. Although appearing
promising for treatment regimes in pSS, first studies into
their effects on pSS patients were disappointing, and did not
improve symptoms, including dryness [54].
Focusing now on the SG epithelium, SGECs have been
well established to express not only virally associated TLRs
(3 and 7) but also those associated with bacterial infections
(TLRs 1,2,4) [37]. pSS SGECs and labial SGs displayed higher
constitutive expression of TLR1, TLR2, TLR3 TLR4, and
MyD88 mRNA compared with healthy control SGECs. In
the labial SG of pSS patients, the acinar and ductal epithe-
lial cells strongly expressed TLR2, TLR3, TLR4, and MyD88.
Ductal and acinar epithelial cells in pSS parotid glands
expressed TLR7 and TLR9 but were found to be limited to
the ductal epithelial cells only in the controls [55]. When
SGECs were treated with the TLR2, 3 and 4 ligands, dose-
dependent upregulation of ICAM-1, CD40, and MHC-I
expression was observed; moreover, compared to control
SGECs, SGECs from pSS patients displayed significant and
constitutive higher gene expression of TLR1, 2 and 4 [39].
TLR signaling in the SG epithelium is therefore active and its
blockade is likely to also affect the SG epithelium. The SG
epithelium relies on many signaling pathways for its home-
ostasis. One such pathway is epithelial growth factor (EGF)
signaling. In relation to TLR signaling, EGF receptor (EGFR)
activation has also been demonstrated to be necessary for
TLR3 signaling in an epithelial cell line, and for the TLR-
4-mediated activation of the downstream NF-κB pathway,
albeit in a cancer cell line model system [56,57]. Vice versa,
TLR4 signaling also activates EGFR signaling, activates pro-
liferation in intestinal epithelial cells and regulates expres-
sion of EGFR ligands [58]. In terms of rescuing SG
parenchymal balance in pSS, we would suggest that TLR
Table 1. Summary of small-molecule inhibitors discussed in this review.





Innate immune response TLR (3.1) CpG-52,364 NO NO [47,48]
ST2825 NO NO [53]
NFκB (3.2) Iguratimod NO YES (I/II) [64]
GS-9876 NO YES (II) –
JAK-STAT (3.3) Filgotinib YES YES (II) [73,74]
Tofacitinib NO NO –
Ruxolitinib NO NO –
Epithelial cell
homeostasis
Autophagy (4.1) Rapamycin NO NO [28,29,98,99]
LY294002 YES NO [100]
Wortmannin YES NO [100]
Apoptosis (4.2) None tested NO NO
Rho kinase (4.3) (4.2) Y-27,632 YES NO [91,102,103,104,105,106,108,109]
H-1152 YES NO [103]
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blockade is not the foremost candidate for therapeutic use
based on its cross-talk with the EGF pathway.
3.2. Inhibitors of NFkB signaling
The nuclear factor kappa B (NFκB) family is a group of tran-
scription factors, capable of activating an array of inflamma-
tory downstream targets, when permitted to translocate to
the nucleus. Their activation can be achieved through both
a canonical or non-canonical pathway. The five members of
the NFκB family (RelA, RelB, c-Rel, NFκB1, and NFκB2) form
homo- or heterodimers with each other, together with the
inhibitory molecule IκB. The canonical NFκB pathway is acti-
vated by proinflammatory cytokines such as IL-1β and TNFα,
that bind to their respective receptors and also by binding of
(PAMPS) to the TLRs. Engagement of both types of receptors
triggers activity of the IKK (IκB kinase) complex, culminating in
phosphorylation IκB proteins in the inhibitory NFκB complex.
Phosphorylated IκB is then degraded, and released NKκB
translocate to the nucleus and activate target gene transcrip-
tion. The non-canonical pathway operates via a slightly differ-
ent mechanism, and given the expression of CD40 on ductal
epithelial cells, is also likely to be operational in pSS. For the
purpose of this review however and considering which drugs
are currently in clinical trials for pSS treatment, we will focus
only on the canonical pathway.
In pSS, overall phosphorylated IKKε, responsible for degrada-
tion of IkB proteins, and NFκB levels were positively and signifi-
cantly correlated with biopsy focus score, infiltration grade and
overall disease activity measured [59]. The levels of BAFF and
a large group of proinflammatory cytokines, which are all regu-
lated by NFκB signaling, are elevated in pSS [60,61]. Single
nucleotide polymorphisms in NFκB pathway genes have been
associated with pSS [62], and a specific mutation in the promoter
for a member of the inhibitory IkB complex, IkBα-826T, was
associated with susceptibility for pSS [63]. Numerous SMIs of
the NFκB signaling pathways are currently commercially avail-
able for use. Currently, two drugs acting as NFκB modulators are
in clinical trial phases for treatment of pSS. Iguratimod is a new
synthetic DMARD show to have anti–inflammatory effects in
animal models of arthritis or other autoimmune diseases, and
preventing activation of the NFκB signaling pathway through as
yet unclear mechanisms [64]. A phase 2 trial using the Syk-
inhibitor GS-9876 is also currently in progress. Syk-signaling lies
upstream of IKK activation, and its blockade results in amelio-
rated NFκB release from its inhibitory complex.
Numerous preclinical studies have examined the role of the
NFκB pathway in the SG epithelium in pSS. The NFκB pathway
has been soundly demonstrated to be active in pSS SGECs.
Phosphorylated IKKε (pIKKε), pIκBα, and pNFκB were all highly
expressed in ductal epithelium in minor SGs from pSS patients
[65]. Expression of the NFκB inhibitor IκBα, which inhibits NFκB
activity by masking its nuclear localization signals, was signifi-
cantly lower in SGECs from pSS biopsies than in healthy con-
trols [65,66]. Stimulating the TLR2 receptor in SGECs induced
IL-2 production via the NFκB pathway in pSS SGECs [67,68].
Treating SGECs with pSS anti-Ro/SSA autoantibodies resulted
in a progressive increase in binding of NFκB to DNA, and
transfection of SGECs with IκB-α in anti-Ro/SSA-treated
SGECs lead to a marked reduction of proinflammatory cyto-
kines gene expression and an increase in apoptosis [26,69]. In
a human SG cell line, upregulation of IL-6 was regulated by
a group of pathways including NFκB [70]. Our recent study
demonstrated that knock-out of the natural NFκB inhibitor
A20 in K14+ epithelial cells (and thus constitutive pathway
activation) was sufficient to trigger the initial phases of pSS,
including reduced saliva production, and lymphocyte invasion
of the SGs [38]. Although detailed studies focusing on the SG
are lacking, there may also be a degree of interplay between
the NFκB pathway and acinar cell calcium signaling, whereby
calcium signaling is essential for NFκB pathway activity [71]. In
pSS patients with reduced saliva flow but minimal lymphocytic
infiltration, acinar cell calcium signaling was found to be
reduced, and in a separate study employing neuronal cells,
blockade of NFκB signaling interfered with function of the
membrane calcium channel proteins Orai1/STIM1/2 [10]. If
these data can be extrapolated to SG acinar cells, the effect
of NFκB blockade via SMIs on acinar cell function may further
exacerbate problems with saliva secretion, by disruption of
calcium signaling. These studies aside, no studies directly
checking the effect of NFκB SMIs on SGECs have been per-
formed. Cross talk between the NFκB and EGF signaling path-
ways is mediated via TLR signaling, as discussed in section 3.1.
Theoretically, SMIs targeted against NFκB signaling should
exert minimal collateral damage on EGFR signaling, which
remains a problem with TLR blockade, and should also dam-
pen the inflammatory process.
3.3. Inhibition of JAK-STAT signaling
JAK and STAT intracellular messengers relay a membrane-bound
signal to the nucleus, through means of dimerization in various
combinations of JAK (four members: JAK1,2,3 and TYK2) and
transcription factor STAT (seven members: STAT1, 2, 3, 4, 5A,
5B, and 6) family constituents. JAK-STAT signaling is initiated by
binding of cytokines to their respective receptors on the cell
surface and is utilized by more than 50 cytokines. Cytokine
binding induces receptor multimerization, which permits cross-
phosphorylation of cytoplasmic JAK kinase. JAKs then activate
members of the STAT family by phosphorylation, facilitating their
migration to the nucleus and activation of downstream targets.
STAT proteins tend to activate defined gene sets. These sets can
be broadly grouped into four types of effector responses, but
which can vary depending on cell type and tissue origin of the
signal transducing cell. In lymphocytes, activation of STAT1 and
STAT4 drives production of an anti-viral Th1 response, STAT6
a Th2 response, STAT3 a Th17 response, and STAT5 an anti-
inflammatory Treg response. A defined role for STAT2 remains
unclear. Considering the established type-1 interferon signature,
one can hazard a guess that blockade of JAK-STAT signaling may
be considered of therapeutic applicability in pSS. A common
upstream denominator of cytokine receptors associated with
these response profiles appears to be JAK1, narrowing down
the potential choice of JAK inhibitors in pSS [72]. A clinical trial
with filgotinib, a selective JAK1 inhibitor, is currently in progress
in pSS, the outcomes of which will be eagerly awaited. Two other
clinically approved JAK1 inhibitors, tofacitinib (blocking JAK1 and
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JAK3) and ruxolitinib (blocking JAK1 and JAK2) remain to be
extensively tested in pSS. Focusing on peripheral blood,
Vartoukian et al. [73] demonstrated the potential utility of target-
ing JAK-STAT, when reporting that SOCS3, a negative regulator
of the JAK-STAT pathway, was itself dysregulated in peripheral
blood of pSS patients [73]. Filgotinib treatment also reduced
IFNα-induced IFIT1 and IFIT2 gene expression, and membrane-
bound BAFF expression in SGECs from lip biopsies [74,75]. We
have also demonstrated recently that SGPCs react to proinflam-
matory cytokines by proliferation and apparent cell death, pre-
sumably by signaling through the JAK-STAT pathway, implying
that inhibitors of JAK-STAT signaling may also interfere with the
homeostasis of the SG epithelium [20].
The SG epithelium, including its progenitor cells, is char-
acterized by its reliance on EGF and Wnt signaling for home-
ostasis, amongst others [18,76,77]. EGF signaling is mediated
by several mechanisms including by JAK-independent activa-
tion of the STAT3 [78–80]. The influence of JAK inhibitors
such as filgotinib on EGFR signaling via STAT3 is currently
unclear, and will likely be crucial to the stability of the
epithelium following JAK1 inhibition. Another pathway sali-
ent to the function of many epithelial cell populations is the
TGF/SMAD system. Expression of TGFβ family members is
associated with differentiation of SGPCs into acinar cells
[81]. Activation of the JAK-STAT pathway may result in
enhanced activity of the TGF signaling messenger SMAD7,
promoting thus SGPC differentiation. Theoretically, JAK-STAT
blockade may prevent acinar cell formation, and eventual
saliva production [82]. Interestingly, SMAD7 activation also
enables STAT3 activation.
A third pathway salient to epithelial cell survival and of
relevance to JAK-STAT inhibition is the Wnt signaling pathway.
Wnt signaling has been demonstrated to be crucial to numer-
ous adult stem cell populations, and supplementation of cell
culture medium with members of the Wnt family permits
generation of mini-SGs in the laboratory [20,76]. The intracel-
lular intricacies of the Wnt pathway reveal a degree of cross-
talk with the JAK-STAT pathway. Binding of the Wnt3a ligand
to its extracellular receptor in a retinal epithelial cell line has
been shown to activate STAT3 [83]. STAT3 has additionally
been implicated in the nuclear translocation of β-catenin,
a process crucial to Wnt-pathway activation [84]. Vice versa,
T-cell factor (TCF), a binding element for a member of the Wnt
pathway, was discovered in the STAT3 promoter [85]. β-
catenin also induced STAT3 transcription and mRNA/proteins
levels, providing robust evidence of the interplay between the
two pathways [85]. Knockout of adenomatous polyposis coli
(APC), a negative regulator of the Wnt pathway, resulted in
activation of the JAK-STAT signaling pathway, albeit it in a fly
model [86].
All in all, these data imply that despite the likely efficacy of
JAK-STAT blockade in terms of resolving inflammation, there
are likely to be numerous detrimental effects on the home-
ostasis of the SG epithelium. JAK-STAT signaling inhibition will
affect diverse cellular processes in the SG parenchyme, includ-
ing epithelial (SGPC) proliferation and differentiation, as
a curious interactive web exists between JAK STAT signaling,
and at least three important epithelial cell/epithelial stem cell
signaling pathways [87].
4. Manipulation of epithelial cell survival
mechanisms
The parenchyme of the SG is maintained by proliferation and
differentiation of progenitors cells, which replace exhausted or
damaged functional cells. These damaged cells presumably
undergo apoptosis and are cleared from the tissue. SGECs
from pSS biopsies are more sensitive for apoptosis, which
can reportedly be induced by anti Ro and La autoantibodies
[26,27,42,88,89]. Apoptosis represents therefore an interesting
therapeutic modality.
A second homeostatic pathway that should be considered
in terms of potential therapeutic utility is the autophagy path-
way. Recent studies have also demonstrated the salience of
the autophagy system, a cellular resources recycling system,
for maintenance of tissue parenchyma in general [90]. During
stress situations, the autophagic machinery recycles cellular
resources to enable their applications where most needed.
Autophagy has been demonstrated to be less active in pSS,
pointing to a need to normalize this imbalance in order to
restore saliva production [28,29].
A third category of SMIs not generally associated with the
immune system but of potential importance to the SG epithe-
lium are the small Rho GTPases. Inhibition of downstream
targets of Rho GTPases tends to promote proliferation in
epithelial cells [91]. The striated duct epithelial cells in pSS,
in addition to becoming apoptotic, are widely proliferative.
These proliferative events have been linked, in combination
with concurrent B-cell proliferation and differentiation, to the
development of MALT lymphomas in pSS patients, and repli-
cation-induced senescence of the progenitor cell compart-
ment [20]. Here we consider SMIs inhibiting these three
pathways, in relation to their potential application in pSS.
SMIs aimed therefore at restoring SG epithelial cell home-
ostasis by blocking apoptosis, promoting autophagy or mod-
ulating epithelial cell proliferation are therefore also worthy of
consideration in the context of therapeutic angles aimed at
restoring saliva production.
4.1. Inhibitors of apoptosis
Apoptosis is a form of programmed cell death. SGECs from
pSS patients have been well characterized to be more sensi-
tive to apoptosis [42,88]. Curiously, basal cells of the SG
striated ducts in healthy and pSS tissue were found to express
the anti-apoptotic protein Bcl2, and thus be relatively resistant
to apoptosis [92]. Acinar cells, of both controls and patients
conversely, did not express Bcl2. How this relates to the
enhanced apoptosis in SGECs from pSS patients in the pSS
epithelium is not clear, and reiterates the doubts about which
cells exactly are found in SGEC cultures.
In terms of aiming to restore homeostasis of the SG in pSS,
normalization of the levels of apoptosis would seem to repre-
sent a sensible goal. To date, no studies employing SMIs
targeted against the apoptotic machinery in pSS have been
reported, whilst tens of these drugs exist. Targeting specifically
the hyperproliferative epithelium will also be challenging.
Apoptosis is also part of the regular turnover of the SG,
when exhausted saliva-producing acinar cells die, and are
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replaced with new cells generated from progenitor cells.
Enhanced EGF signaling, critical to epithelial cell and SGPC
homeostasis, and also involved with STAT3-based cytokine
signaling, can also result in apoptosis [93]. This provides an
additional explanation for enhanced apoptotic levels observed
in the epithelium of pSS patients, and also further confirms the
complicity of STAT3 in a multitude of salient pathways. Use of
SMIs targeting the JAK-STAT pathways may therefore also
reduce EGFR-mediated epithelial cell apoptosis, although this
has never been tested. The prevention of epithelial cell apop-
tosis under broad anti-apoptotic SMI application may have
undesirable consequences for the SG epithelium as a whole
and immune system in general but in lieu of experimental
data, we can only speculate how this may manifest.
4.2. Inhibitors of the mTOR pathway
Classical literature states that autophagy is a survival
mechanism for cells under stress conditions. It can be
viewed as a mechanism for degrading and recycling cellular
resources, and broadly speaking antagonizes apoptosis,
although this is still fiercely under debate [90]. If not cor-
rectly recycled, these cellular components have been sug-
gested to contribute to autoimmune phenotypes, including
pSS [94]. The autophagy pathway can be broadly subdivided
into that mediated by mTOR1 or mTOR2 subcellular signal-
ing units, with mTOR1 being both the most well character-
ized, and likely responsible for protein clearance and
autophagy. An active mTOR1 pathway inhibits autophagy.
Interestingly, TLR stimulation has been shown to initiate
autophagy, termed then ‘immunological autophagy’ [95,96],
and vice versa that autophagy can negatively regulate TLR
signaling (reviewed in [97]). mTOR inhibitors, such as the
mTOR1-specific compound rapamycin, promote an active
autophagy system and protein clearance. When salivary
gland lymphocytes from of pSS patients were examined,
numbers of T-, B-, and plasma cells with mTOR activity
were elevated compared to controls, and were further asso-
ciated with local and systemic B-cell hyperactivity [28]. Most
strikingly, proliferation of B-cells, ɣT-cells, Tc cells, CCR9+ Th
cells, and IgG production halted in vitro with mTOR inhibi-
tion [28]. Studies relating specifically to the SG parenchyme
and autophagy are fairly preliminary. In a comparison of
minor SGs from patients with pSS scleroderma and systemic
sclerosis, elevated activity of the mTOR pathway (and thus
inhibited autophagy) was observed in the epithelium as
a whole, although the lack of a healthy control comparison
makes the results of this study challenging to interpret [29].
Proctor et al. showed that application of rapamycin, and
thus increased autophagy, in a duct ligation injury model
transiently stabilized the atrophic murine SG, although this
effect was relatively short-lived [98]. Confirming the interac-
tion of the autophagy pathway with the innate immune
system, TLR9 stimulation in immortalized human SG cells
has recently been demonstrated to increase autophagy [99].
The autophagic pathway of epithelial cells is intricate and
intertwined with many cellular processes in addition to apop-
tosis and TLR signaling. For example, EGFR signaling leads to
active PI3K signaling, downstream increased mTOR activity,
and hence decreased autophagy. Targeting of PI3K kinases
with SMIs, for example, LY294002 and wortmannin, may
remove this blockade of autophagy, and improve saliva pro-
duction according to a recent mouse study, but at the
expense of EGFR signaling critical to SG epithelial cell survival
[100]. As discussed in section 3.1, EGFR signaling itself func-
tions mechanistically in a similar manner to cytokines, and is
likely to be elevated in pSS, and therefore potentially also
contributing to the reduced activity of the autophagy machin-
ery in pSS. Stabilization of autophagy in the SG epithelium in
pSS would seem a logical, but knock-on effects of tampering
with the autophagy machinery on all these additional path-
ways may make it a less desirable option.
4.3. Inhibitors of small Rho GTPases
Small Rho kinases mediate a host of signals emanating from
surface receptors, the extracellular matrix, and mechanical
stresses. Their activation culminates in inhibition of cell cycle
progression, amongst other outcomes [101]. Rho kinase sig-
naling plays a critical role in epithelial cell biology and Rho
kinase inhibitors, blocking the action of Rho-ROCK down-
stream of Rho kinase, promote human epithelial cell prolifera-
tion. Proliferation of limbal epithelial cells was promoted dose-
dependently in an in vitro culture system and epithelial wound
closure rate was shown to be faster with application of
Y-27,632, a Rho-ROCK inhibitor [102]. Treating epithelial cells
from various tissues with Y-27,632 increased the total number
of epithelial cells harvested, by promoting their prolifera-
tion [91].
In SGs, the effect of Rho kinase has been extensively stu-
died from SG development and epithelium polarization to
epithelium apoptosis and does not appear to be so clear cut.
Firstly, Rho kinase is essential for the development of SGs.
A study from William’s group showed that Y-27,632 and
H-1152 Rho-ROCK inhibitors stalled submandibular gland
branching morphogenesis at the cleft initiation stage [103].
Small Rho GTPases are also important for acinar formation
from human SG cell lines [104,105]. Secondly, Rho kinase
also exerts a strong effect on epithelial polarization. Li et al.
reported the inhibition of Rho kinase abolished correct distri-
bution of tight junction proteins, potentially influencing saliva
secretion given the role of tight junctions in paracellular trans-
port of fluid [106]. The activated Rho kinase signaling pathway
is also involved in the apoptosis of SG epithelial cells, and
when in vitro cultured mouse SG stem cells were incubated
with Y-27,632, expression of senescence-related proteins p16
and p21 was downregulated, and cellular proliferation was
enhanced [107,108]. Another study using Y-27,632 to treat
mouse SG in vitro also suggested increased cell adhesion,
viability, migration, and proliferation [109].
Inhibition of the Rho kinase pathway using agents such as
Y-27,632 appears may therefore be both beneficial and detri-
mental to the SG epithelium, dependent on the cell type in
question, and process the cell is undergoing at the time of
application. If proliferation of epithelial cells is observed with
Rho-ROCK application, extended application of Rho kinase
inhibitors on pSS patients might however not be advisable,
with respect to undesirable SGPC exhaustion induced by
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replicative senescence. Transient exposure at the appropriate
timing therefore may be a potentially useful therapeutic
option in order in combination with stronger anti-
inflammatory SMIs, to help rescue SG function in pSS.
5. Conclusion
Small-molecule inhibitor use in treatment of autoimmune dis-
eases is likely to increase dramatically in the coming years,
given their potential to inhibit specific signaling pathways. We
have considered here the possible effects of SMIs likely to be
employed to treat pSS, on the salivary gland epithelium. We
would like to propose a two-cell model, to explain these
possible effects (Figure 3). We predict that the ‘first’ epithelial
cell transmitting a TLR or NFκB signal represents a less com-
plicated target for SMI applications. Specifically, NFκB inhibi-
tion does not appear to interfere directly with EGFR signaling,
according to current knowledge, or other salient epithelial
pathways. More studies will of course be necessary to confirm
this. SMI application to block JAK-STAT signaling in a cytokine
signal–receiving epithelial cell (the ‘second’ cell) is likely to
interfere with a barrage of signaling pathways critical to
epithelial cell homeostasis (Figure 2). SMIs targeted against
the autophagy, apoptosis and small GTPases also represent
modulation of complicated cellular machinery, which also
interact with both immune signaling pathways and other
important epithelial cell systems (Figure 2). The role of STAT3
as a junction between many signaling pathways is also appar-
ent, when pathways affected by the SMIs examined are ‘com-
bined’ into one cell. Based on this cross talk and its potential
effects on the EGF, Wnt, and TGF signaling pathways, we
would propose that SMIs that tamper with STAT3 homeostasis
should be avoided, when attempting to both resolve inflam-
mation and rescue the function of the SG in pSS. Figure 3
shows a grossly oversimplified two-cell model of potential SMI
interference points. In reality, both processes of the first
and second epithelial cells may also take place via autocrine
signaling in the same epithelial cell. In this scenario, with no
divisible up- or – down-stream components to target, a choice
of SMI becomes even more challenging. If further research
concludes indeed that all SMIs will detrimentally effect the
SG epithelium, an alternative approach may be required.
Figure 3. Summary of documented cross-talk between cellular pathways in salivary gland epithelial cells that are potentially affected by small-molecule inhibitor use. Red
highlighted boxes indicate likely critical mediators of the effect of inflammation in the salivary gland in primary Sjögren’s syndrome. For the sake of illustration, toll-
like receptors are represented in the membrane of the cell, and not additionally in the endosomes.
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Modern technology using patient-specific induced-pluripotent
cells (iPS cells), capable of making all cell types in the body,
could be employed to generate new SG progenitor cells.
Further genetic modification of these fresh SGPCs may addi-
tionally prevent them becoming activated by immune signals,
and their transplantation into the patients SG could in princi-
ple rescue the damaged SG.
6. Expert opinion
Primary SS is an autoimmune inflammatory disease, often
depicted by loss of exocrine gland function and lymphocytic
infiltration of the exocrine glands, in addition to chronic fatigue
and autoantibody production. In the case of the salivary gland,
hyposalivation is commonly observed in the clinic, and carries
with it an obligation to use lubricating aids in order to speak, eat,
sleep and chew properly, and continuing dental problems.
Hyposalivation confers a dramatic decrease in quality of life for
the patient, and its resolution represents an unmet clinical need.
The small molecular inhibitors are a new class of drugs with
a small weight that allows their movement into cells, and
interference with very specific members of many different
signaling pathways. These pathways include the NFκB and
JAK-STAT pathways belonging to the immune system, and
the autophagy, apoptosis and Rho GTPase pathways grouped
here under the heading of epithelial cell survival mechanisms.
The small molecular inhibitors discussed in this review are
either already in use for treatment of pSS (alone or in combi-
nation with DMARDs), or likely to be trialed in the coming
years. Their effect of the SG epithelium, the tissue type that
must recover in order for hyposalivation to be alleviated in
pSS, is paramount in choice of the SMI used, and should not
be ignored. Having carefully reviewed available literature and
knowledge regarding epithelial cell biology, we would like to
first emphasize the importance of the epithelium in the choice
of SMI made. If inflammation is resolved using a particular SMI,
but the homeostasis of the SG is destroyed in the process, its
application with regard to recovery of saliva production is
debatable. In our opinion and based on current data, SMIs
targeting the NFκB receptors may represent the optimum
choice with the least collateral damage to the epithelium,
although this remains to be fully tested. Any potential future
applications are limited at present by the scarcity of exhaus-
tive studies examining the effect of the full spectrum of SMIs
on the SG epithelium. Ideally, these studies should include
a treatment of SMI effect on SG epithelial cell proliferation,
differentiation, and apoptosis, in combination with effective
amelioration of inflammation. We also suggest that a more
widespread employment of SGPC cultures in organoid format
is necessary, where the full repertoire of parenchymal cells in
the SG can be examined, and will be key to unraveling the
effects of SMIs on the SG epithelium in the coming years. We
predict furthermore the emergence of the field of immune–
parenchyme interactions in general as one of the most impor-
tant and potentially influential fields in medicine in the current
scientific climate, as we acknowledge the capability of tissues
such as the SG epithelium to actively participle in disease
pathology.
With every new wave of drugs discovered comes the hurry to
apply them to relevant patient groups. In the case of pSS and
small molecular inhibitors, this brings with it not inconsiderable
risks for the parenchyme of the SG in pSS. Broadening the scope,
we would suggest that the core message of our review also
applies to other autoimmune diseases with an epithelial cell
component, for example, Crohn’s disease, where the same
mechanisms and pathway cross-talk are likely to exist.
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